Navigation Links
Research Gets Closer to Origin of Parkinson's Disease
Date:1/4/2008

Modified protein hastens nerve cell death, scientists say

FRIDAY, Jan. 4 (HealthDay News) -- The nerve cell death that helps drive Parkinson's disease may be triggered by a harmful modification in a particular nerve cell protein, new research reveals.

The modification in question -- an apparently toxic mix of the protein alpha-synuclein and the critical neurotransmitter dopamine -- can be found in all Parkinson's patients, researchers say.

The change short-circuits a process that allows aging nerve cells to stay healthy by purging themselves of damaged molecules, researchers explain in the Jan. 2 online issue of The Journal of Clinical Investigation.

"The general idea is that, in Parkinson's, the neurons accumulate lots of garbage," explained study author Dr. Ana Maria Cuervo, an associate professor in the department of anatomy and structural biology at Yeshiva University's Albert Einstein College of Medicine, in New York City.

"Normally," she said, "this garbage is removed before it builds up, and is dumped into garbage containers called lysosomes, which make sure things can move about the neurons fast and freely."

Such a filtering process for disposing of damaged molecules is known as "autophagy," a term that literally means "self-eating."

"But sometimes, this mechanism fails," Cuervo noted. "And now we have found the reason why. It is because of the formation of this particular modified protein, which acts kind of like chewing gum in the middle of the nerve cell."

"It's not a normal protein," she stressed. "It's very sticky, and any other proteins passing by get stuck to it, so you get all these abnormal things, these stones in the middle of the cell's highways, that are not being removed, and eventually the [brain] cells can't move things around as they should, and they die."

In an earlier effort, the same research team had found that mutant forms of alpha-synuclein -- as opposed to modified forms -- also block the desired breakdown of damaged nerve cell molecules. Such mutant proteins are present in the 5 percent to 10 percent of Parkinson's patients struck with a relatively rare, familial form of the disease.

"But the novelty of our work today is that the modified protein mechanism we found this time will apply to all Parkinson's patients," noted Cuervo. "And so it becomes possible that in the future we can design drugs to improve the function of the garbage containers, the lysosomes, in all Parkinson's patients, and maybe overcome the problem that these nerve cells have handling the modified molecules."

Cuervo and her Einstein colleagues conducted the study, based on laboratory work with male rats, in collaboration with scientists from Columbia University in New York City, the University of Pennsylvania, and Harvard Medical School in Boston.

The National Parkinson Foundation estimates that 1.5 million Americans are affected with Parkinson's disease, the most common degenerative brain disorder affecting movement.

The nerve damage that's characteristic of this incurable disease brings about a dramatic loss of muscle control, typically manifesting as tremors, stiffness, and a loss of balance and agility.

Though optimistic about her work, Cuervo emphasized that translating the latest findings into new preventive and curative interventions will require a lot more research and time.

"I want to be very cautious," she said. "We are far from a final cure. It's not something we can do tomorrow. It's going to take some time. But now we know what the problem is. And we think that we have something, a target, to focus on."

Nonetheless, Dr. Robert Burke, director of the Morris K. Udall Parkinson's Disease Research Center of Excellence at Columbia University, called the new findings a "big step forward."

"Their first finding was only related to the mutant form of the protein which is very rare," he noted. "Whereas here they have shown that dopamine-modified neurons also block the system. This means they now have something that appears applicable to patients with the much more common sporadic form of Parkinson's. And that is very, very helpful."

More information

For more on Parkinson's disease, head to the Parkinson's Disease Foundation.



SOURCES: Ana Maria Cuervo M.D., Ph.D, associate professor, department of anatomy and structural biology, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Yeshiva University, New York City; Robert Burke, M.D., director, Morris K. Udall Parkinson's Disease Research Center of Excellence, Columbia University, New York City; Jan. 2, 2008, Journal of the Clinical Investigation online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. amfAR announces inaugural Mathilde Krim Fellowship Awards for AIDS research
2. Researchers use neuroimaging to study ESP
3. UGA researchers receive $9 million in grants to study barriers to effective addiction treatment
4. Jan Marini Skin Research Gives Familiar Logo a Facelift
5. Researchers seek to make cavity-causing bacteria self-destruct
6. Research suggests new treatment suitable for all patients
7. 2007: A Watershed Year for Lupus Research and Education
8. FASgen Announces New Research Discoveries in Lung Cancer
9. Human factors researchers test voting systems for seniors that can improve voting accuracy and speed
10. New research tools are too complex for easy answers, researchers say
11. Research Offers Promise for Cirrhosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Research Gets Closer to Origin of Parkinson's Disease
(Date:5/23/2017)... ... May 23, 2017 , ... Axiad IDS , a leading provider ... magazine has named the company a “Top 25 Cybersecurity Companies 2017.” Axiad ... help organizations simply and proactively address potential cybersecurity threats before they happen. The ...
(Date:5/23/2017)... ... 23, 2017 , ... PM360, the premier information resource for ... winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • Leaders • ... industry today. , Out of more than 500 submissions, 100 winners were selected ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of ... Worthy of a Policy Response”, -The Rory Staunton Foundation Calls on Health & Human ... the Prevention of Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a new study released ...
(Date:5/23/2017)... ... 23, 2017 , ... The National Council on Strength and ... the organization’s Certified Strength Coach credential has earned accreditation from the National Commission ... the competency of qualified candidates for jobs in the Strength and Conditioning profession. ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment option called ... elastin in their face, neck, and body through a virtually pain-free, non-surgical treatment. ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017  Demonstrating its commitment ... of directors for the Pharmaceutical Research and Manufacturers ... membership. Biopharmaceutical companies will now have to meet ... to be eligible to join PhRMA. ... board is sending a clear message that being ...
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
(Date:5/4/2017)... MONTREAL , May 4, 2017  Fortuna Fix Inc. (" ... aiming to be the first to eliminate the need for ... autologous cells to treat neurodegenerative diseases. Fortuna ... ("SAB") with Professor Michael Fehlings , MD, PhD; Father ... Hack , MD, MPH; and Professor James Giordano , ...
Breaking Medicine Technology: